ApprovalTrail

Drug · DIN 02417030

BEXSERO

MULTICOMPONENT MENINGOC. B VACCINE (R-DNA ADSORBED). 0.5ML PFS.

Yes: authorized and sold in Canada

Authorized, and the company reports that it sells it in Canada.

Status Marketed since September 8, 2016; first marketed February 26, 2014.
Drug Identification Number (DIN)
02417030
Company (DIN owner)
Glaxosmithkline IncMississauga, Ontario, Canada
Schedule
Schedule d
Dosage form
Suspension
Route
Intramuscular
Therapeutic class (ATC)
Meningococcus b, multicomponent vaccine J07AH09
Class
Human
Record last updated
February 10, 2026

Active ingredients

As listed in the Drug Product Database.

IngredientStrengthPer
RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN50 MCG0.5 ML
RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN50 MCG0.5 ML
RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN50 MCG0.5 ML
OUTER MEMBRANE VESICLES (NEISSERIA MENINGITIDIS GROUP B NZ98/254 STRAIN)25 MCG0.5 ML

Notices of Compliance

Health Canada approvals that name this DIN.